E-mail: sebejova.ludmila@fnbrno.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- ATM INACTIVATION DISTURBS ATM-P53 PATHWAY IN RESPONSE TO DNA DAMAGE INDUCED BY DOXORUBICIN BUT NOT FLUDARABINE IN CLL CELLS
- Clonal Evolution and Therapy Related Selection Of TP53 Mutations In Chronic Lymphocytic Leukemia Patients
- DEEP SEQUENCING IDENTIFIES TP53 MUTATIONS BEFORE THEIR CLONAL SELECTION BY THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
- Defects of ATM Gene Involving Mutation Lead to Complete Elimination of ATM Function in Chronic Lymphocytic Leukemia
- DETAILED MUTATIONAL ANALYSIS OF TP53 GENE REVEALS HIGH INCIDENCE OF ADDITIONAL MINOR PROPORTION MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
- EVALUATION OF TP53 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA USING RESEQUENCING MICROARRAY PLATFORMS
- CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE HIGHLY SUSCEPTIBLE TO DIRECT INHIBITION OF CHECKPOINT KINASE 1
- Inhibition of Chk1 Kinase Sensitizes Leukemia and Lymphoma Cell Lines with TP53 Mutations to Chemotherapy
- MISSENSE MUTATIONS LOCATED IN STRUCTURAL P53 DNA-BINDING MOTIFS ARE ASSOCIATED WITH EXTREMELY POOR SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
- MUTATION STATUS OF ATM GENE IN CLL PATIENTS HARBORING DELETION 11Q OR TP53 DEFECT
- Mutational Analysis of Mir-29 Family Members in Chronic Lymphocytic Leukemia
- Mutational Analysis of TP53 Gene in Chronic Lymphocytic Leukemia: Comparison of Different Methodological Approaches
- Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life
- REACTIVATION OF SELECTED P53 MUTANTS IN B-CELL TUMOR CELL LINES USING TARGETED SMALL MOLECULES
- SF3B1 Mutations Frequently Occur With Both ATM Mutations and TP53 Mutations In CLL Patients
- SYNTHETIC LETHALITY IN P53 MUTATED B-CELL MALIGNANCIES: CHK-1 INHIBITION AND DNA-PK INHIBITION EFFECT IN CELL LINES AND PRIMARY CLL CELLS
- T315I MUTATIONS ARE CLUSTERED WITH ADVANCED PHASES CONTRARY TO OTHER ABERRATIONS IN CML PATIENTS RESISTANT TO TKI THERAPY
- THE IMPACT OF SPECIFIC MUTATIONS IN TP53 GENE ON THE RESULTS OF ALEMTUZUMAB THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
- TP53 MUTATIONS BUT NOT ATM MUTATIONS ASSOCIATE WITH HIGHER IN VITRO RESISTANCE OF CLL CELLS TO RITUXIMAB
